Advertisement

Related Videos

Opening Session Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Mar
09
Today In Oncology
TACE With Camrelizumab and Rivoceranib in Unresectable Hepatocellular Carcinoma
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
Cumulative Incidence of Advanced Breast Cancer in Japanese Women Aged 40 to 49 Years With Addition of Ultrasonography to Mammography Screening
HPV Vaccination Protection From Cervical Cancer Sustained Long Term
Five-Year Outcomes With First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo